Literature DB >> 28687576

NCCN Guidelines Insights: Antiemesis, Version 2.2017.

Michael J Berger, David S Ettinger, Jonathan Aston, Sally Barbour, Jason Bergsbaken, Philip J Bierman, Debra Brandt, Dawn E Dolan, Georgiana Ellis, Eun Jeong Kim, Steve Kirkegaard, Dwight D Kloth, Ruth Lagman, Dean Lim, Charles Loprinzi, Cynthia X Ma, Victoria Maurer, Laura Boehnke Michaud, Lisle M Nabell, Kim Noonan, Eric Roeland, Hope S Rugo, Lee S Schwartzberg, Bridget Scullion, John Timoney, Barbara Todaro, Susan G Urba, Dorothy A Shead, Miranda Hughes.   

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis address all aspects of management for chemotherapy-induced nausea and vomiting. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Antiemesis, specifically those regarding carboplatin, granisetron, and olanzapine.
Copyright © 2017 by the National Comprehensive Cancer Network.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28687576     DOI： 10.6004/jnccn.2017.0117

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  43 in total

1.  Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.

Authors:  Ronald Chow; David G Warr; Rudolph M Navari; May Tsao; Marko Popovic; Leonard Chiu; Milica Milakovic; Henry Lam; Carlo DeAngelis
Journal:  Support Care Cancer       Date:  2018-05-23       Impact factor: 3.603

2.  The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Authors:  Veerisa Vimolchalao; Siwat Sakdejayont; Ploytuangporn Wongchanapai; Shama Sukprakun; Pattama Angspatt; Wilai Thawinwisan; Piyachut Chenaksara; Virote Sriuranpong; Chanida Vinayanuwatikun; Napa Parinyanitikun; Nattaya Poovorawan; Suebpong Tanasanvimon
Journal:  Int J Clin Oncol       Date:  2019-11-27       Impact factor: 3.402

3.  Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Authors:  Tiago Nava; Marc Ansari; Jean-Hugues Dalle; Christina Diaz de Heredia; Tayfun Güngör; Eugenia Trigoso; Ulrike Falkenberg; Alice Bertaina; Brenda Gibson; Andrea Jarisch; Adriana Balduzzi; Halvard Boenig; Gergely Krivan; Kim Vettenranta; Toni Matic; Jochen Buechner; Krzysztof Kalwak; Anita Lawitschka; Akif Yesilipek; Giovanna Lucchini; Christina Peters; Dominik Turkiewicz; Riitta Niinimäki; Tamara Diesch; Thomas Lehrnbecher; Petr Sedlacek; Daphna Hutt; Arnaud Dalissier; Jacek Wachowiak; Isaac Yaniv; Jerry Stein; Koray Yalçin; Luisa Sisinni; Marco Deiana; Marianne Ifversen; Michaela Kuhlen; Roland Meisel; Shahrzad Bakhtiar; Simone Cesaro; Andre Willasch; Selim Corbacioglu; Peter Bader
Journal:  Bone Marrow Transplant       Date:  2020-02-06       Impact factor: 5.483

4.  Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.

Authors:  Lee Schwartzberg; Rudolph Navari; Rebecca Clark-Snow; Ekaterine Arkania; Irena Radyukova; Kamal Patel; Daniel Voisin; Giada Rizzi; Rita Wickham; Richard J Gralla; Matti Aapro; Eric Roeland
Journal:  Oncologist       Date:  2019-12-04

5.  Reality of the emetogenic level of irinotecan.

Authors:  Maria-Angeles Garcia-Del-Barrio; Salvador Martin-Algarra; Azucena Aldaz Pastor
Journal:  Support Care Cancer       Date:  2018-04-21       Impact factor: 3.603

6.  Prognostic significance of hyponatremia induced by systemic chemotherapy in a hospital-based propensity score-matched analysis.

Authors:  Yosuke Sugiyama; Taku Naiki; Yoshihiko Tasaki; Yuki Kondo; Tomoya Kataoka; Toshiki Etani; Keitaro Iida; Satoshi Nozaki; Ryosuke Ando; Satoshi Osaga; Takahiro Yasui; Kazunori Kimura
Journal:  Int J Clin Oncol       Date:  2019-12-06       Impact factor: 3.402

7.  Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy.

Authors:  Tobias Janowitz; Sam Kleeman; Robert H Vonderheide
Journal:  Oncologist       Date:  2021-02-26

8.  Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects.

Authors:  Zhi-Yi Zhang; Jing Wang; Vikram Kansra; Xiaodong Wang
Journal:  Invest New Drugs       Date:  2018-07-21       Impact factor: 3.850

9.  Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.

Authors:  Zhonghan Zhang; Yaxiong Zhang; Gang Chen; Shaodong Hong; Yunpeng Yang; Wenfeng Fang; Fan Luo; Xi Chen; Yuxiang Ma; Yuanyuan Zhao; Jianhua Zhan; Cong Xue; Xue Hou; Ting Zhou; Shuxiang Ma; Fangfang Gao; Yan Huang; Likun Chen; Ningning Zhou; Hongyun Zhao; Li Zhang
Journal:  Oncologist       Date:  2018-01-12

10.  Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis.

Authors:  Masato Karayama; Naoki Inui; Kazuki Tanaka; Hideki Yasui; Hironao Hozumi; Yuzo Suzuki; Kazuki Furuhashi; Tomoyuki Fujisawa; Noriyuki Enomoto; Yutaro Nakamura; Takafumi Suda
Journal:  Med Oncol       Date:  2018-09-05       Impact factor: 3.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.